Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Co.'s multi-therapeutic pipeline has a primary focus on neurodegeneration and its primary program utilizing IkT-148009, c-Abl inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. Co. is also developing platform technologies for alternate ways to deliver protein kinase inhibitors in patients.
Company Name: |
Inhibikase Therapeutics Inc |
Website: |
www.inhibikase.com |
Sector: |
Biotechnology |
Number of ETFs Holding IKT: |
1 |
Total Market Value Held by ETFs: |
$29100 |
Total Market Capitalization: |
$12.00M |
% of Market Cap. Held by ETFs: |
0.24% |
|
|
April 27, 2024 12:28 PM Eastern
Strong Buy (4.00 out of 4)
89th percentile
|
|